FDA Approves Lucentis Biosimilar Nufymco - Summary - MDSpire

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

  • By

  • Conexiant News Staff

  • January 2, 2026

  • 1 min

Share

Objective:

To announce the FDA approval of Nufymco, a biosimilar of Lucentis, for various ophthalmic conditions.

Key Findings:
  • Nufymco is a biosimilar of Lucentis.
  • FDA approval covers multiple ophthalmic conditions.
  • Zydus Lifesciences will handle marketing in the US.
Interpretation:

The approval of Nufymco represents a significant advancement in the availability of affordable treatment options for patients with serious eye conditions, enhancing access to care.

Limitations:
Conclusion:

The approval of Nufymco highlights Bioeq's commitment, alongside its partners, to expanding access to high-quality biosimilars in the ophthalmic field.

Original Source(s)

FDA Approves Lucentis Biosimilar Nufymco

  • by Conexiant News Staff

  • January 2, 2026

Related Content

Advancing Retinal Imaging for Cardiovascular Risk Assessment

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

Inner retinal layer thickness reflects plasma biomarkers in preclinical Alzheimer’s disease